Treatment with CSE (5%, 24 h) significantly increased fibronectin expression in both the control (132.1%) and ASMCs of COPD patients (210.9%) when compared to non-treated cells (Figure 3A). This evidence concerns the gene FN1 and chronic obstructive pulmonary disease.